Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley ratsShow others and affiliations
2017 (English)In: Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, E-ISSN 1432-0843, Vol. 80, no 2, p. 317-332Article in journal (Refereed) Published
Abstract [en]
Purpose: Chemotherapy-induced gastrointestinal toxicity (CIGT) is a complex process that involves multiple pathophysiological mechanisms. We have previously shown that commonly used chemotherapeutics 5-fluorouracil, oxaliplatin, and irinotecan damage the intestinal mucosa and increase intestinal permeability to iohexol. We hypothesized that CIGT is associated with alterations in fecal microbiota and metabolome. Our aim was to characterize these changes and examine how they relate to the severity of CIGT.
Methods: A total of 48 male Sprague-Dawley rats were injected intraperitoneally either with 5-fluorouracil (150 mg/kg), oxaliplatin (15 mg/kg), or irinotecan (200 mg/kg). Body weight change was measured daily after drug administration and the animals were euthanized after 72 h. Blood, urine, and fecal samples were collected at baseline and at the end of the experiment. The changes in the composition of fecal microbiota were analyzed with 16S rRNA gene sequencing. Metabolic changes in serum and urine metabolome were measured with 1 mm proton nuclear magnetic resonance (1H-NMR).
Results: Irinotecan increased the relative abundance of Fusobacteria and Proteobacteria, while 5-FU and oxaliplatin caused only minor changes in the composition of fecal microbiota. All chemotherapeutics increased the levels of serum fatty acids and N(CH3)(3) moieties and decreased the levels of Krebs cycle metabolites and free amino acids.
Conclusions: Chemotherapeutic drugs, 5-fluorouracil, oxaliplatin, and irinotecan, induce several microbial and metabolic changes which may play a role in the pathophysiology of CIGT. The observed changes in intestinal permeability, fecal microbiota, and metabolome suggest the activation of inflammatory processes.
Place, publisher, year, edition, pages
Springer, 2017. Vol. 80, no 2, p. 317-332
Keywords [en]
Chemotherapy, Metabolomics, Microbiota, 5-FU, Oxaliplatin, Irinotecan
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:oru:diva-83107DOI: 10.1007/s00280-017-3364-zISI: 000406638200010PubMedID: 28646338Scopus ID: 2-s2.0-85021203470OAI: oai:DiVA.org:oru-83107DiVA, id: diva2:1439750
Note
Funding Agencies:
Cancer Society of Finland
Finska Läkaresällskapet
Foundation of Clinical Chemistry Research
Biomedicum Helsinki Foundation
Ministry of Economy and Competitiveness of Spain SAF2014-52875R
Instituto de Salud Carlos III
European Union (EU) PIE15/00013
2020-06-122020-06-122020-06-12Bibliographically approved